clinical trial · NCT02408549
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
UCB BIOSCIENCES, Inc.·phase3·completed·n = 239
EpilepsyLacosamide TabletLacosamide Oral Solution
brief summary
Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects \>= 4 years of age with idiopathic generalized epilepsy (IGE). This study will enroll subjects from the LCM SP0982 \[NCT02408523\] study.
started
Aug 3, 2015
primary completion
Mar 30, 2023
completion
Mar 30, 2023
last updated
Dec 14, 2023
official title
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol